SCHEMBL22622671

SCHEMBL22622671

N[C@H]1CN(c2ccc(C(F)(F)F)cc2)C(=O)c2c(-c3ccc4nccn4c3)cnn21

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 20/20 0.82
KCNH2 Q12809 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22492733 0.90 GRM2 (1.00) GRM2KCNH2
SCHEMBL22622632 0.90 GRM2 (0.82) GRM2KCNH2
Hydrochloric Acid SCHEMBL30422448 0.89 GRM2 (0.98) GRM2KCNH2
SCHEMBL22622649 0.88 GRM2 (0.81) GRM2
SCHEMBL22622568 0.88 GRM2 (0.81) GRM2KCNH2
SCHEMBL22622569 0.88 GRM2 (0.82) GRM2
SCHEMBL22950511 0.86 GRM2 (0.62) GRM2KCNH2
SCHEMBL22622670 0.85 GRM2 (0.83) GRM2
SCHEMBL22622585 0.85 GRM2 (0.83) GRM2KCNH2
SCHEMBL22622619 0.84 GRM2 (0.82) GRM2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210850-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES Sumitomo Pharma Co., Ltd. (JP) 2023-07-06 US disclosed
US-10953008-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-03-23 US disclosed
US-20210030754-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-02-04 US disclosed
US-20200345729-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210850-A1 PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES CYP3A5, CYP2F1, CYP4Z1 GRM2 3682/4885KCNH2 275/4885
US-20200345729-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF GRM5, GRM6, GRM2 GRM2 3/4885KCNH2 1372/4885
US-10953008-B2 Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor GRM5, GRM1, GRM2 GRM2 3/4885KCNH2 880/4885
US-20210030754-A1 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF GRM5, GRM6, GRM2 GRM2 3/4885KCNH2 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.